secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001193125-24-147583
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios sells vorasidenib royalty rights to Royalty Pharma for $905M upfront upon FDA approval
--------------------------------------------------------------------------------

- Royalty Pharma pays $905M to Agios upon FDA approval of vorasidenib (PDUFA date Aug 20, 2024).
- Agios retains $200M milestone from Servier upon approval; total potential cash inflow of ~$1.1B.
- Royalty Pharma receives 15% royalty on first $1B annual US sales; Agios retains 3% on sales above $1B.
- Proceeds intended to fund PYRUKYND launches in thalassemia/sickle cell and expand pipeline.
- Transaction closing requires FDA approval by Oct 31, 2024 and other customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312524147583/0001193125-24-147583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312524147583/d717537d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-147583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer